We selected this combination based on our prior research demonstrating the enhanced therapeutic efficacy of vinorelbine in Renal Cell Cancer (RCC) when combined with antiangiogenic therapy using a VEGF-neutralizing antibody14. Here, VEGFA is linked to renal cell adenocarcinoma.